目的 建立高效液相色谱-串联质谱法(LC-MS/MS)测定人血浆中氯法拉滨浓度。方法 采用API3000串联质谱仪及Shimadzu系列液相色谱仪进行检测。血浆样品经乙酸乙酯提取处理,以克拉屈滨为内标。色谱柱为Thermo C18柱(4.6 mm×150 mm,5 μm),流动相为乙腈-水(250∶3,其中含4 mmol的乙酸铵和0.3%的甲酸),流速为0.5 mL·min-1。氯法拉滨和克拉屈滨的MRM扫描离子通道m/z分别为304.0→170.0,286.1→170.0。进样体积为20 μL,每个样品的分析时间为5 min。结果 氯法拉滨和克拉屈滨保留时间分别为4.00,4.11 min。氯法拉滨在10~2 000 ng·mL-1内线性关系良好(r=0.999 5),日内、日间RSD均低于9.60%,准确度为101.10%~102.94%。结论 本法样品预处理简便快速,检测准确、灵敏、专一,适用于氯法拉滨药动学的研究。
Abstract
OBJECTIVE To establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of clofarabine in human plasma. METHODS The drug was determinated by LC-MS/MS using electrospray ionization. The plasma samples were extracted with ethyl acetate. Cladribine was the internal standard (IS). The analytical column was Thermo C18 column (4.6 mm×150 mm,5 μm). The mobile phase consisted of acetonitrile-water (250∶3,Which contains 4 mmol of ammonium acetate and 0.3% formic acid) at a flow rate of 0.5 mL·min-1. Clofarabine and cladribine were detected on multiple reaction monitoring (MRM) by the transitions from the precursor to the product ion (m/z 304.0/170.0 and m/z 286.1/170.0). The injection volume was 20 μL and the total run time was 5.0 min. RESULTS Calibration curve showed good linearity in the range of 10-2 000 ng·mL-1 (r=0.999 5). The intra-batch and inter-batch precisions (RSD) were all less than 9.60% and the accuracy was within 101.10%-102.94%. CONCLUSION The retention time of cladribine and clofarabine were 4.00 and 4.11 min. The established LC-MS/MS method is sensitive,accurate and simple for the determination of clofarabine in human plasma. It is suitable for the pharmacokinetics of clofarabine.
关键词
氯法拉滨 /
高效液相色谱-串联质谱法 /
血浆浓度
{{custom_keyword}} /
Key words
clofarabine /
LC-MS/MS /
drug plasma concentration
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ZHAO J, CHEN X F. Capillary gas chromatographic determination of residual solvents in clofarabine in raw material [J]. Pharm Clin Res (药学与临床研究) , 2008, 16(4): 330-332.
[2] NIE Y L, FU D X, HU X, et al. A new therapeutic agent for leukemia: clofarabine [J]. Chin J New Drugs(中国新药杂志), 2007, 16(10): 821-824.
[3] JUDITH E K, REBECCA M R, KUMUDHA B, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias [J]. Clin Trials Observations, 2007, 110(6): 1762 - 1769.
[4] YUNSHENG H, CHRISTINE J G D, SUINING L, et al. Comparision of fast liquid chromatography/tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma [J] . J Pharm Biom Anal, 2007, 44(2): 492 - 497.
[5] VARSHA G, HAGOP K, STEFAN F, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias[J].Clin Cancer Res, 2003, 9(12): 6335 - 6342.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}